Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Gastric Cancer
100%
Signaling Pathway
100%
Tailored Management
100%
Precision Therapy
100%
Recent Updates
100%
Hepatocyte Growth Factor
66%
C-Met
66%
Progression-free Survival
66%
Programmed Death-ligand 1 (PD-L1)
66%
Tyrosine Kinase
33%
Therapeutic Strategies
33%
Poor Prognosis
33%
Overall Survival
33%
Microenvironment
33%
Advanced Stage
33%
Best Response
33%
Gastric Carcinoma
33%
Optimal Treatment
33%
Chemoresistance
33%
Aberrations
33%
MTOR Inhibitor
33%
Significant Benefit
33%
Novel Agents
33%
Aberrant Expression
33%
Lapatinib
33%
Target of Rapamycin Kinase
33%
Gastric Cancer Progression
33%
Mammalian Target of Rapamycin Signaling Pathway
33%
P-STAT3
33%
Regorafenib
33%
Immune Checkpoint
33%
Gastric Cancer Prognosis
33%
Activator of Transcription 3
33%
Phosphoinositide 3-kinase/Akt
33%
Biologic Roles
33%
Janus Kinase 2/signal Transducer
33%
Protein Tyrosine Phosphatase SHP2
33%
Durable Efficacy
33%
Programmed Cell death-1/programmed Cell Death-ligand 1
33%
MET Antibody
33%
Pharmacology, Toxicology and Pharmaceutical Science
Abdominal Cancer
100%
Progression Free Survival
40%
Scatter Factor
40%
Clinical Study
20%
Carcinogenesis
20%
Phosphatidylinositol 3 Kinase
20%
Overall Survival
20%
STAT3 Protein
20%
Protein Tyrosine Phosphatase
20%
Protein Tyrosine Kinase
20%
Cancer Growth
20%
Drug Resistance
20%
Protein Kinase B
20%
Mammalian Target of Rapamycin Inhibitor
20%
Mammalian Target of Rapamycin
20%
Programmed Cell Death
20%
Janus Kinase 2
20%
Lapatinib
20%
Biological Product
20%
Regorafenib
20%
Programmed Death 1 Ligand 1
20%